ATE417054T1 - Steuerbare phosphofructokinase und der warburg effekt - Google Patents

Steuerbare phosphofructokinase und der warburg effekt

Info

Publication number
ATE417054T1
ATE417054T1 AT98957451T AT98957451T ATE417054T1 AT E417054 T1 ATE417054 T1 AT E417054T1 AT 98957451 T AT98957451 T AT 98957451T AT 98957451 T AT98957451 T AT 98957451T AT E417054 T1 ATE417054 T1 AT E417054T1
Authority
AT
Austria
Prior art keywords
ipfk
phosphofructokinase
controllable
warburg effect
cancer
Prior art date
Application number
AT98957451T
Other languages
English (en)
Inventor
Richard Bucala
Jason A Chesney
Robert A Mitchell
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Application granted granted Critical
Publication of ATE417054T1 publication Critical patent/ATE417054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
AT98957451T 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt ATE417054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/961,578 US6413939B1 (en) 1997-10-31 1997-10-31 Inducible phosphofructokinase and the Warburg effect

Publications (1)

Publication Number Publication Date
ATE417054T1 true ATE417054T1 (de) 2008-12-15

Family

ID=25504669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957451T ATE417054T1 (de) 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt

Country Status (10)

Country Link
US (4) US6413939B1 (de)
EP (1) EP1042350B1 (de)
JP (1) JP4369044B2 (de)
AT (1) ATE417054T1 (de)
AU (1) AU1370799A (de)
CA (1) CA2308091A1 (de)
DE (1) DE69840342D1 (de)
ES (1) ES2319345T3 (de)
IL (1) IL135887A0 (de)
WO (1) WO1999023108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0216097D0 (en) * 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
WO2006065967A2 (en) * 2004-12-15 2006-06-22 General Atomics Allosteric enzyme coupled immunoassay (aecia)
WO2006102191A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8662667B2 (en) * 2007-12-21 2014-03-04 Carl Zeiss Meditec Ag Ophthalmologic visualization system
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
US9012242B2 (en) * 2010-09-20 2015-04-21 Caliper Life Sciences Multivalent fluorescent probes
DK2532747T3 (en) * 2011-06-09 2016-01-25 Deutsches Krebsforsch Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513571A (ja) * 1995-10-24 1999-11-24 ガーヴァン インスティチュート オブ メディカル リサーチ プロゲスチンにより制御される遺伝子
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect

Also Published As

Publication number Publication date
WO1999023108A9 (en) 1999-08-19
US6413939B1 (en) 2002-07-02
CA2308091A1 (en) 1999-05-14
JP2001521731A (ja) 2001-11-13
US20030228568A1 (en) 2003-12-11
AU1370799A (en) 1999-05-24
EP1042350B1 (de) 2008-12-10
IL135887A0 (en) 2001-05-20
EP1042350A4 (de) 2003-01-02
US6596851B1 (en) 2003-07-22
ES2319345T3 (es) 2009-05-06
US6255046B1 (en) 2001-07-03
JP4369044B2 (ja) 2009-11-18
DE69840342D1 (de) 2009-01-22
EP1042350A1 (de) 2000-10-11
WO1999023108A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
ATE417054T1 (de) Steuerbare phosphofructokinase und der warburg effekt
Jacobi et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
Millard et al. Determination of the DNA crosslinking sequence specificity of reductively activated mitomycin C at single-nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially
Waldron et al. Endoplasmic reticulum calcium pump expression and control of cell growth.
US6573284B1 (en) Method of treating melanoma
BR0108025A (pt) Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
EP1379251A4 (de) Hemmstoffe der akt aktivität
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
WO2000047215A3 (en) Methods for anti-tumor therapy
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
Moysan et al. Formation of cyclobutane thymine dimers photosensitized by pyridopsoralens: quantitative and qualitative distribution within DNA
WO2001085219A3 (en) Identification, diagnosis, and treatment of breast cancer
WO2002024947A3 (en) Cancer associated protein kinases and their uses
DE69330137D1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
HUP0300007A2 (en) Antibody with specificity for colon cancer
Gallo et al. Reverse transcriptase from Mason-Pfizer monkey tumor virus, avian myeloblastosis virus, and Rauscher leukemia virus and its response to rifamycin derivatives
DE69534197D1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
Hightower et al. In vitro evaluation of the novel chemotherapeutic agents U-73, 975, U-77, 779, and U-80, 244 in gynecologic cancer cell lines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042350

Country of ref document: EP